Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical trial in a controlled setting to learn more about allergies caused by house dust
To evaluate the dose-related efficacy of MK-8237 sublingual house dust mite (HDM) tablet versus placebo in the treatment of HDM-induced rhinitis based on the average total nasal symptom score (TNSS) d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Reformulated raltegravir (1200 mg) once a day versus raltegravir (400 mg) twice a day in treatment-naïve patients
Evaluate the effectiveness of reformulated raltegravir 1200 mg given once daily plus TRUVADA™, compared to raltegravir 400 mg given twice daily plus TRUVADA™, measured by the proportion of subjects wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Research done in healthy human volunteers to Investigate how the MK-8342B (ENG-E2, 125/300 µg/day) Vaginal Ring behaves in and influences the body of female Postmenarcheal Adolescents and Healthy Female Adults. Forschung an gesunden Freiwilligen zu untersuchen, wie MK - 8342B (ENG E2, 125/300 g / Tag) Vaginalring sich verhält und den weiblichen Körper von Jugendlichen Mädchen (welche die Periode haben) und gesunder weiblicher Erwachsene beeinflusst
Objective 1: To investigate the pharmacokinetics of ENG, E2 and E1 (estrone) following administration of MK-8342B (ENG-E2, 125/300 μg/day) vaginal ring in healthy female postmenarcheal adolescents (≥1...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer. Estudio de pembrolizumab en monoterapia frente a quimioterapia con agente único para cáncer de mama triplemente negativo metastásico
1st Objective: To compare progression-free survival (PFS) based on RECIST 1.1 as assessed by blinded central imaging vendor in subjects with PD-L1 positive tumors. 2nd Objective: To compare PFS base...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Study Comparing Pragmatic Use of Vernakalant and Amiodarone Treatments in the Emergency Room Management of Patients with Recent Onset Atrial Fibrillation
To determine whether the primary use of vernakalant results in a higher proportion of patients discharged from the ER to home, home-equivalent, or LTCF within 12 hours from randomization compared to t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab versus SOC in 1L Subjects with PD-L1 Strong Metastatic NSCLC
1. To compare the progression free survival per RECIST 1.1 as assessed by blinded independent central radiologists’ review in subjects with PD-L1 strong, 1L metastatic NSCLC treated with MK-3475 compa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
MK-5592 Protocol 069 (POS vs VOR for the treatment of a fungal infection (Invasive Aspergillosis) in Adults and Adolescents
Compare global clinical response of POS vs VOR in the first-line treatment of invasive aspergillosis at Week 6 in those subjects with proven or probable invasive aspergillosis (FAS population). The hy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with Rheumatoid Arthritis
Objective 1: To compare the effects of etoricoxib 90 mg vs. placebo after 6 weeks of treatment Objective 2: To compare the effects of etoricoxib 60 mg vs. placebo after 6 weeks of treatment in Part I ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical trial to assess the safety and efficacy of MK-1293 compared to Lantus? in treatment of Diabetes Mellitus. Estudio clínico para valorar la seguridad y eficacia MK-1293 en comparación con Lantus? en el tratamiento de diabetes mellitus
1. To assess the effect of treatment with MK-1293 compared with Lantus? on anti-insulin antibody development after 24 weeks of treatment. 2. To assess the non-inferiority of treatment with MK-1293 c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A clinical study in patients with complicated infections of the urinary tract conducted to assess safety, tolerability and efficacy of the study drug (MK-7655) administered together with Imipenem/Cilastatin (an antibiotic) in comparison with Imipenem/Cilastatin administered alone
- To evaluate the efficacy of 2 doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg) with respect to the microbiological response assessment profile in the treatment of adult patients with cUTI,...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant